Overview
- Wegovy, a once-weekly GLP-1 receptor agonist, debuted across India on June 24 in five dosing strengths delivered via a pen device and approved for long-term weight management and cardiovascular risk reduction.
- India’s obesity burden is substantial, with 254 million people classified as generally obese and 351 million suffering from abdominal obesity, according to ICMR-INDIAB statistics.
- Novo Nordisk aims to leverage its established insulin distribution network in India and is pursuing $1 billion in Wegovy revenue over the next five to seven years.
- Eli Lilly’s rival, Mounjaro (tirzepatide), launched in India in March, has already generated significant early sales, intensifying market competition.
- Novo Nordisk ended its partnership with Hims & Hers over alleged deceptive marketing of compounded semaglutide and braces for generic entries after the semaglutide patent expires in March 2026.